Profile data is unavailable for this security.
About the company
Indivior PLC is a pharmaceutical company. The Company develops medicines to treat addiction and serious mental illnesses. The Company focuses on building a portfolio of opioid dependence treatments. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Its product pipeline focuses on development and discovery of non-opioid treatment strategies for opioid use disorder (OUD), as well as therapies to address the needs of people suffering from alcohol, stimulant, and cannabis use disorders. Its Sublocade, Subutex, and Suboxone are used for the treatment of opioid use disorder (OUD). Perseris is used for the treatment of Schizophrenia. The Company's pipeline products include AEF0117, INDV-2000, INDV-1000, RBP-6000, RBP-7000, Buprenorphine Sublingual and Naloxone Film, and Buprenorphine and Naloxone Sublingual Tablet. Its pipeline also includes the Orexin-1 Receptor Antagonist Program.
- Revenue in GBP (TTM)896.04m
- Net income in GBP3.99m
- Incorporated2014
- Employees1.05k
- LocationIndivior PLC10710 Midlothian TurnpikeSuite 125, North ChesterfieldCHESTERFIELD 23235United StatesUSA
- Phone+0 (804) 379-1090
- Websitehttps://www.indivior.com/en
Peer analysis
Company | Revenue (TTM) | Net income (TTM) |
---|---|---|
Cosmo Pharmaceuticals NV | 82.92m | 983.28k |
Fagron NV | 654.35m | 60.50m |
Biotest AG | 587.12m | 108.92m |
Genus plc | 673.10m | 33.40m |
Bavarian Nordic A/S | 812.27m | 169.67m |
Evotec SE | 670.16m | -71.97m |
Galapagos NV | 251.63m | 26.34m |
Dermapharm Holding SE | 973.69m | 53.49m |
Almirall SA | 767.15m | -33.00m |
Vitrolife AB | 257.69m | -282.51m |
Worldwide Healthcare Trust PLC | -66.33m | -95.44m |
Indivior PLC | 896.04m | 3.99m |
BB BIOTECH AG | 238.28m | 270.85m |
Camurus AB | 126.44m | 31.77m |
MorphoSys AG | 174.52m | -391.37m |
Virbac SA | 1.07bn | 104.03m |
Institutional shareholders
Holder | Shares | % Held |
---|---|---|
Two Seas Capital LPas of 28 Mar 2024 | 13.56m | 9.97% |
Morgan Stanley & Co. International Plcas of 31 Dec 2023 | 9.74m | 7.17% |
Soci�t� G�n�rale Gestion SAas of 12 Apr 2024 | 6.48m | 4.77% |
Scopia Capital Management LPas of 19 Mar 2024 | 6.29m | 4.63% |
Madison Avenue Partners LPas of 14 Nov 2023 | 4.63m | 3.40% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 4.46m | 3.28% |
Goldman Sachs Internationalas of 31 Dec 2023 | 4.39m | 3.23% |
Fidelity Management & Research Co. LLCas of 29 Feb 2024 | 3.70m | 2.72% |
BlackRock Investment Management (UK) Ltd.as of 31 Mar 2024 | 3.35m | 2.47% |
Norges Bank Investment Managementas of 31 Dec 2023 | 2.85m | 2.10% |